welcomes you to the new, improved website!
Michel Ménassa
Video
Since the publication of the results of the CheckMate 816 trial (1), neoadjuvant chemoimmunotherapy has been introduced as a standard of care for stage IB-IIIA resectable NSCLC without mutations. The use of minimally invasive approaches...